Disease · MONDO_0006058
Wilms tumor
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Wilms tumor. Diseases, record MONDO_0006058. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006058
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs32
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DACTINOMYCIN | CHEMBL1554 | Protein | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| VINCRISTINE | CHEMBL90555 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| DOXORUBICIN HYDROCHLORIDE | CHEMBL359744 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| IRINOTECAN | CHEMBL481 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| VINCRISTINE SULFATE | CHEMBL501867 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| FILGRASTIM | CHEMBL1201567 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 32
See all 32 drugsTargets42
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 42
See all 42 targetsTrials28
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00352534 | Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor | Phase 3 | 808 | 2017-05-15 | Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor | DACTINOMYCIN, DOXORUBICIN, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00379340 | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor | Phase 3 | 395 | 2017-06-14 | Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor | CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT00945009 | Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor | Phase 3 | 249 | 2019-03-05 | Adult Kidney Wilms Tumor, Beckwith-Wiedemann Syndrome, Childhood Kidney Wilms Tumor, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Rhabdoid Tumor of the Kidney, Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor, Stage V Kidney Wilms Tumor | DACTINOMYCIN, DOXORUBICIN HYDROCHLORIDE, VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | Phase 2 | 118 | 2017-06-05 | Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Kidney Neoplasm, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma | ALISERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Phase 2 | 109 | 2022-11-28 | Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue, Clear Cell Sarcoma of Soft Tissue, Ewing Sarcoma, Hepatoblastoma, Hepatocellular Carcinoma, Osteosarcoma, Recurrent Adrenal Cortical Carcinoma, Recurrent Alveolar Soft Part Sarcoma, Recurrent Clear Cell Sarcoma of Soft Tissue, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Kidney Wilms Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Renal Cell Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Medullary Carcinoma, Refractory Adrenal Cortical Carcinoma, Refractory Alveolar Soft Part Sarcoma, Refractory Clear Cell Sarcoma of Soft Tissue, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Renal Cell Carcinoma, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Medullary Carcinoma, Refractory Wilms Tumor, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Neoplasm, Thyroid Gland Medullary Carcinoma, Wilms Tumor | CABOZANTINIB S-MALATE | Its record names the disease | ClinicalTrials.gov |
| NCT02452554 | Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma | Phase 2 | 62 | 2019-08-29 | Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Recurrent Synovial Sarcoma, Wilms Tumor | LORVOTUZUMAB MERTANSINE | Its record names the disease | ClinicalTrials.gov |
| NCT01502410 | Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer | Phase 2 | 20 | 2015-05-15 | Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Thyroid Cancer, Recurrent Wilms Tumor and Other Childhood Kidney Tumors | SORAFENIB TOSYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT00993044 | A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin | Phase 1 | 13 | 2014-07-23 | Refractory Solid Tumors in Children | BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00002611 | Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer | Phase 3 | 3,031 | Kidney Cancer | CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE, FILGRASTIM, VINCRISTINE SULFATE | Its record names the disease | ClinicalTrials.gov | |
| NCT06401330 | A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | 1,656 | Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor | CARBOPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, ETOPOSIDE, IRINOTECAN, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 28
See all 28 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Group 1 Relapsed/Refractory Rhabdomyosarcoma vs Group 2 Relapsed/Refractory Wilms Tumor: serious adverse events | 4 of 10 | 3 of 10 | 20 | NCT01502410 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: serious adverse events | 1 of 6 | 1 of 6 | 12 | NCT00993044 | Trial comparisons |
Papers from its trials36
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006058
GET https://conductscience.org/api/diseases/v1/MONDO_0006058/drugs?page=2